Mycrocept

Mycrocept is a pre-clinical stage biotechnology company developing a proprietary platform for the targeted delivery of immunosuppressive agents. The company's technology, originating from the Langer Lab at MIT, utilizes engineered microparticles to deliver mycophenolic acid directly to macrophages and other phagocytic immune cells. By concentrating the drug within the immune system and reducing systemic exposure, Mycrocept aims to improve the efficacy and safety profile of treatments for organ transplant rejection and various autoimmune disorders. The platform has the potential to transform the management of chronic conditions by mitigating the severe side effects associated with conventional systemic immunosuppressants.